GlassScriptPhysician profile
Michael B Crawford
NPI 1093776502
$2,663.32
in general payments reported to CMS, 2019-2025
23 companies · $130 in 2025
The $130 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,003 · 2020: $610 · 2021: $523 · 2022: $187 · 2023: $85.20 · 2024: $125 · 2025: $130.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $340.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $340.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $776.79 | 2019-2025 | Xtandi |
| Dendreon Pharmaceuticals LLC | $276.16 | 2019-2022 | |
| Pfizer INC. | $252.96 | 2019-2022 | |
| Allergan, INC. | $191.93 | 2019-2021 | |
| Endo Pharmaceuticals INC. | $182.65 | 2019-2021 | |
| Neotract INC. | $167.32 | 2019 | |
| Janssen Biotech, INC. | $144.17 | 2019-2021 | |
| Teleflex LLC | $143.29 | 2021-2023 | Urolift |
| Abbvie INC. | $84.71 | 2019-2023 | Botox |
| Bayer Healthcare Pharmaceuticals INC. | $83.10 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $60.74 | 2020-2021 | |
| Antares Pharma, INC. | $45.92 | 2020-2021 | |
| Ferring Pharmaceuticals INC. | $42.14 | 2019-2020 | |
| Myriad Genetic Laboratories, INC. | $35.79 | 2021 | |
| Coloplast Corp | $29.69 | 2019-2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Laborie Medical Technologies Corp. | $26.25 | 2020 | |
| Myovant Sciences INC. | $23.93 | 2021 | |
| Foundation Medicine, INC. | $23.41 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $19.19 | 2020 | |
| Tolmar Pharmaceuticals, INC. | $18.22 | 2019 | |
| Acerus Pharmaceuticals Corporation | $13.99 | 2020 | |
| Clovis Oncology, INC. | $12.43 | 2020 | |
| Janssen Pharmaceuticals, INC | $8.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Crawford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.